Monoamine oxidase inhibitory action of chalcones: A Mini Review

Central Nervous System Agents in Medicinal Chemistry

Volumn 16, Issue 2, 2016, Pages 120-136

  Mathew, Bijo ^a   Haridas, Abitha ^a   Suresh, Jerad ^b   Mathew, Githa E ^c   Uçar, Gülberk ^d   Jayaprakash, Venkatesan ^e  

^a Grace College of Pharmacy   (India)

^b MADRAS MEDICAL COLLEGE   (India)

^c Grace College of Pharmacy   (India)

^d HACETTEPE UNIVERSITY   (Turkey)

^e BIRLA INSTITUTE OF TECHNOLOGY   (India)

Author keywords

Alzheimer s disease; Chalcones; Depression; MAO A; MAO B

Indexed keywords

ACETYLCHOLINESTERASE; CHALCONE DERIVATIVE; CHROMENYLCHALCONE; COUMARIN; FLUORINATED THIENYLCHALCONE; FURANOCHALCONE; HETEROCYCLIC CHALCONE; ISOLIQUIRITIGENIN; LIQUIRITIGENIN; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE B INHIBITOR; MONOAMINE OXIDASE INHIBITOR; PIPERIDYL THIENYLCHALCONE; QUINOLINYL THIENYLCHALCONE; RASAGILINE; SELEGILINE; UNCLASSIFIED DRUG; AMINE OXIDASE (FLAVIN CONTAINING); MONOAMINE OXIDASE A, HUMAN;

ALZHEIMER DISEASE; BINDING AFFINITY; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CHEMICAL STRUCTURE; DEPRESSION; DRUG ACTIVITY; DRUG DESIGN; ELECTRON TRANSPORT; HUMAN; IC50; MOLECULAR RECOGNITION; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PHARMACOPHORE; RAT; REVIEW; STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMISTRY; METABOLISM;

ANIMALS; CHALCONES; HUMANS; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84973649627     PISSN: 18715249     EISSN: 18756166     Source Type: Journal    
DOI: 10.2174/1871524915666151002124443     Document Type: Review

References (93)

1. Binda, C.; Huba’lek, F.; Li, M.; Edmondson, D.E.; Mattevi A. Crystal structure of human monoamine oxidase B, a drug target enzyme monotopically inserted into the mitochondrial outer membrane. FEBS Lett., 2004, 564, 225-228.
2. Edmondson, D.E.; Mattevi, A.; Binda, C.; Li, M.; Huba’lek, F. Structure and mechanism of monoamine oxidase. Curr. Med. Chem., 2004, 11, 1983-1993.
3. Yamada, M.; Yasuhara, H. Clinical pharmacology of MAO inhibitors: safety and future. Neurotoxicology, 2004, 25, 215-221.
4. Drukarch, B.; van Muiswinkel, F.L. Drug treatment of Parkinson’s disease. Time for phase II. Biochem. Pharmacol., 2000, 59, 1023-1031.
5. Schapira, A.H. Treatment options in the modern management of Parkinson disease. Arch. Neurol., 2007, 64, 1083-1088.
6. Zeller, E.A.; Barsky, J. In vivo inhibition of liver and brain monoamine oxidase by 1-Isonicotinyl-2-isopropyl hydrazine. Proc. Soc. Exp. Biol. Med., 1952, 81, 459-461.
7. Parmar, S.S.; Pandey, B.R.; Dwivedi, C.; Harbison, R.D. Anticonvulsant activity and monoamine oxidase inhibitory properties of1, 3, 5-trisubstituted pyrazolines. J. Pharm. Sci., 1974, 63, 1152-1155.
8. Manna, F.; Chimenti, F.; Bolasco, A.; Secci, D.; Bizzarri, B.; Befani, O.; Turini, P.; Mondovi, B.; Alcaroc, S.; Tafi, A. Inhibition of Amine oxidases activity by 1-Acetyl-3,5-diphenyl-4,5-dihydro- 1(H)-pyrazole derivatives. Bioorg. Med. Chem. Lett., 2002, 12, 3629-3633.
9. Chimenti, F.; Bolasco, A.; Manna, F.; Secci, D.; Chimenti, P.; Befani, O.; Turini, P.; Giovannini, V; Mondovı, B.; Cirilli, R.; Torre, F.L. Synthesis and selective inhibitory activity of 1-Acetyl- 3,5-diphenyl-4,5-dihydro-(1H)-pyrazole derivatives against Monoamine oxidase. J. Med. Chem., 2004, 47, 2071-2074.
10. Chimenti, F.; Maccioni, E.; Secci, D.; Bolasco, A.; Chimenti, P.; Granese, A.; Befani, O.; Turini, P.; Alcaroc, S.; Ortuso, F.; Cirilli, R.; Torre, F.L.; Cardia, M.C.; Distinto, S. Synthesis, Molecular Modeling Studies, and Selective Inhibitory Activity against Monoamine Oxidase of 1-Thiocarbamoyl-3,5-diaryl-4,5-dihydro-(1H)- pyrazole derivatives. J. Med. Chem., 2005, 48, 7133-7122.
11. Chimenti, F.; Bolasco, A.; Manna, F.; Secci, D.; Chimenti, P.; Granese, A.; Befani, O.; Turini, P.; Alcaroc, S.; Ortuso, F. Synthesis and molecular modelling of novel substituted -4-5-dihydro- (1H)-pyrazole derivatives as potent and highly selective monoamine oxidase-A inhibitors. Chem. Biol. Drug. Des., 2006, 67, 206-214.
12. Kelekci, N.G.; Yabanoglu, S, Kupeli, E.; Salgin, U.; Ozen, O.; Ucar, G.; Yesilada, E.; Kendi, E.; Yesilada, A.; Bilgin, A.A. A new therapeutic approach in Alzheimer disease: Some novel pyrazole derivatives as dual MAO-B inhibitors and anti-inflammatory analgesics. Bioorg. Med. Chem. Lett., 2007, 15, 5775-5786.
13. Chimenti, F.; Fioravanti, R.; Bolasco, A.; Manna, F.; Chimenti, P.; Secci, D.; Rossi, F.; Turini, P.; Ortuso, F.; Alcaro Cardia, M.C. Synthesis, molecular modeling studies and selective inhibitory activity against MAO of N1-propanoyl-3,5-diphenyl-4, 5-dihydro- (1H)-pyrazole derivatives. Eur. J. Med. Chem., 2008, 43, 2262-2267.
14. Jayaprakash, V.; Sinha, B.N.; Ucar, G.; Ercan, A. Pyrazoline-based mycobactin analogues as MAO-inhibitors. Bioorg. Med. Chem. Lett., 2008, 18, 6362-6368.
15. Kelekci, N.G.; Koyunoglu, S.; Yabanoglu, S.; Yelekci, K.; Ozgen, O.; Ucar, G.; Erol, K.; Kendi, E.; Yesiladan, A. New pyrazoline bearing 4(3H)-quinazolinone inhibitors of monoamine oxidase: Synthesis, biological evaluation and structural determinants of MAO-A and MAO-B selectivity. Bioorg. Med. Chem., 2009, 17, 675-689.
16. Chimenti, F.; Carradori, S.; Secci, D.; Bolasco, A.; Bizzarri, B.; Chimenti, P.; Granese, A, Yáñez, M.; Orallo, F. Synthesis and inhibitory activity against human monoamine oxidase of N1- thiocarbamoyl-3, 5-di(hetero)aryl- 4, 5-dihydro-(1H)-pyrazole derivatives. Eur. J. Med. Chem., 2010, 45, 800-804.
17. Shaoo, A.; Yabanoglu, S.; Sinha, B.N.; Ucar, G.; Basu, A.; Jayaprakash, V. Towards development of selective and reversible pyrazoline based MAO-inhibitors: Synthesis, biological evaluation and docking studies. Bioorg. Med. Chem. Lett., 2010, 20, 132-136.
18. Maccioni, E.; Alcaro, S.; Orallo, F.; Cardia, M.C.; Distinto, S.; Costa, G.; Yanez, M.; Sanna, M.L.; Vigo, S.; Meleddu, R.; Secci, D. Synthesis of new 3-aryl-4, 5dihydropyrazole-1-carbothioamide derivatives. An investigation on their ability to inhibit monoamine oxidase. Eur. J. Med. Chem., 2010, 45, 4490-4498.
19. Karuppasamy, M.; Mahapatra, S.; Yabanoglu, S.; Ucar G.; Sinha, B.N.; Basu, A.; Mishra, N.; Sharon, A.; Kulandaivelu, U.; Jayaprakash, V. Development of selective and reversible pyrazoline based MAO-A inhibitors: Synthesis, biological evaluation and docking studies. Bioorg. Med. Chem., 2010, 18, 1875-1881.
20. Fioravanti, R.; Bolasco, A.; Manna, F.; Rossi, F.; Orallo, F.; Yanez, M.; Vital, A.; Ortuso, F.; Alcaro, S. Synthesis and molecular modelling studies of prenylated pyrazolines as MAO-B inhibitors. Bioorg. Med. Chem. Lett., 2010, 20, 6479-6482.
21. Mishra, N.; Sasmal, D. Development of selective and reversible pyrazoline based MAO-B inhibitors: Virtual screening, synthesis and biological evaluation. Bioorg. Med. Chem. Lett., 2011, 21, 1969-1973.
22. Jagrat, M.; Behera, J.; Yabanoglu, S.; Ercan, A.; Ucar, G.; Sinha, B.N.; Sankaran, V.; Basu, A.; Jayaprakash, V. Pyrazoline based MAO- inhibitors: Synthesis, biological evaluation and SAR studies. Bioorg. Med. Chem. Lett., 2011, 21, 4296-4300.
23. Senturk, K.; Tan, O.U.; Ciftci, S.Y.; Ucar, G.; Palaska, E. Synthesis and evaluation of human Monoamine oxidase inhibitory activities of some 3,5-Diaryl-N-substituted-4,5-dihydro-1H-pyrazole-1- carbothioamide derivatives. Arch. Pharm. Chem. Lif. Sci., 2012, 345, 695-702.
24. Fioravanti, R.; Desideri, N.; Biava, M.; Monaco, L.P.; Grammatica, L.; Yáñez, M.; Design, synthesis, and in vitro hMAO-B inhibitory evaluation of some 1-methyl-3,5-diphenyl-4, 5-dihydro- 1H-pyrazoles. Bioorg. Med. Chem. Lett., 2013, 23, 5128-5130.
25. Nayak, B.V.; Ciftci-Yabanoglu, S.; Singh, S.; Jagrat, M.; Sinha, B.N.; Ucar, G.; Jayaprakash, V. Monoamine oxidase inhibitory activity of 3,5-biaryl-4,5-dihydro-1H-pyrazole-1-carboxylate derivatives. Eur. J. Med. Chem., 2013, 69, 762-767.
26. Salgın-Goksen, U.; Yabanoglu-Ciftci, S.; Ercan, A.; Yelekci, K.; Ucar, G.; Gokhan-Kelekci, N. Evaluation of selective human MAO inhibitory activities of some novel pyrazoline derivatives. J. Neural. Transm., 2013, 120, 863-873.
27. Morón, J.A.; Campillo, M.; Perez, V.; Unzeta, M.; Pardo, L. Molecular determinants of MAO selectivity in a series of indolylmethylamine derivatives: biological activities, 3D-QSAR/CoMFA analysis, and computational simulation of ligand recognition. J. Med. Chem., 2000, 43, 1684-1691.
28. Prins, L.H.A.; Petzer, J.P.; Malan, S.F. Inhibition of monoamine oxidase by indole and benzofuran derivatives. Eur. J. Med. Chem., 2010, 45, 4458-4466.
29. Reniers, J.; Robert S.; Frederick, R.; Masereel, B.; Vincent, S.; Wouters, J. Synthesis and evaluation of β-carboline derivatives as potential monoamine oxidase inhibitors. Biorg. Med. Chem., 2011, 19, 134-144.
30. Legoabe, L.; Kruger, J.; Petzer, A.; Bergh, J.J.; Petzer JP. Monoamine oxidase inhibition by selected anilide derivatives. Eur. J. Med. Chem., 2011, 46, 5162-5174.
31. Strydom, B.; Bergh, J.J.; Petzer JP. 8-Aryl- and alkyloxycaffeine analogues as inhibitors of monoamine oxidase. Eur. J. Med. Chem., 2011, 46, 3474-3485.
32. Rendenbach-Müller, B; Schlecker, R.; Traut, M.; Weifenbach, H. Synthesis of coumarins as subtype-selective inhibitors of monoamine oxidase inhibitors. Bioorg. Med. Chem. Lett., 1994, 4, 1195-1198.
33. Catto, M.; Nicolotti, O.; Leonetti, F.; Carotti, A.; Favia, A. D.; Soto-Otero, R.; Méndez-Álvarez, E.; Carotti, A. Structural Insights into Monoamine Oxidase Inhibitory Potency and Selectivity of 7- Substituted Coumarins from Ligand- and Target-Based Approaches. J. Med. Chem., 2006, 49, 4912-4925.
34. Matos, M. J.; Viña, D.; Quezada, E.; Picciau, C.; Delogu, G.; Orallo, F.; Santana, L.; Uriarte, E. A new series of 3-phenyl coumarins as potent and selective MAO-B inhibitors. Bioorg. Med. Chem. Lett., 2009, 19, 3268-3270.
35. Secci, D.; Carradori, S.; Bolasco, A.; Chimenti, P.; Yanez, M.; Ortuso, F.; Alcaro, S. Synthesis and selective human monoamine oxidase inhibition of 3-carbonyl, 3-acyl, and 3-carboxyhydrazido coumarin derivatives. Eur. J. Med. Chem., 2011, 46, 4846-4852.
36. Matos, M. J.; Dolores Viña, D.; Vazquez-Rodriguez, S.; Uriarte, E.; Santana, L. Focusing on new monoamine oxidase inhibitors: Differently substituted coumarins as an interesting scaffold. Curr. Top. Med. Chem., 2012, 12, 2210-2239.
37. Abdelhafez, O.M.; Amin, K.M.; Ali, H.A.; Abdalla, M.M.; Batran, B.Z. Monoamine oxidase A and B inhibiting effect and molecular modeling of some synthesized Coumarin derivatives. Neurochem. Int., 2013, 62, 198-209.
38. Han, Y.N.; Noh, D.B.; Han, D.S. Studies on the monoamine oxidase inhibitors of medicinal plants I. Isolation of MAO-B inhibitors from Chrysanthemum indicum. Arch. Pharm. Res., 1987, 10, 142-147.
39. Ryu, S.Y.; Han, Y.N.; Han, B.H. Monoamine oxidase-A inhibitors from medicinal plants. Arch. Pharm. Res., 1988, 11, 230-239.
40. Sloley, B.D.; Urichuk, L.J.; Morley, P.; Durkin, J.; Shan, J.J.; Pang, P.K.T. et al. Identification of kaempferol as a monoamine oxidase inhibitor and potential neuroprotectant in extracts of Ginkgo biloba leaves. J. Pharm. Pharmacol., 2000, 52, 451-459.
41. Houa, W.C.; Lin, R.D.; Chena, C.T.; Lee, M.H. Monoamine oxidase B (MAO-B) inhibition by active principles from Uncaria rhynchophylla. J. Ethano. Pharmacol., 2005, 100, 216-220.
42. Hwang, J.S.; Lee, S.A.; Hong, S.S.; Le, K.S.; Le, M.K.; Hwang, B.Y. et al. Monoamine oxidase inhibitory components from the roots of Sophora flavescens. Arch. Pharm. Res., 2005, 28, 190-194.
43. Chimenti, F.; Cottiglia, F.; Bonsignore, L.; Casu, L.; Casu, M.; Floris, C et al. Quercetin as the active principle of hypericum hircinum exerts a selective inhibitory activity against MAO-A: Extraction, biological analysis, and computational study. J. Nat. Prod., 2006, 69, 945-949.
44. Bukhari, S.N.A.; Jantan, J.; Jasamai, M. Anti-inflammatory trends of 1, 3-diphenyl-2-propen-1-one derivatives. Mini Rev. Med. Chem., 2013, 13, 87-94.
45. Nowakowska, Z. A review of anti-infective and anti-inflammatory chalcones. Eur. J. Med. Chem., 2007, 42, 125-137.
46. Singh, P.; Anand, A.; Kumar, V. Recent developments in biological activities of chalcones: A mini review. Eur. J. Med. Chem. 2014, 85, 758-777.
47. Karthikeyan, C.; Moorthy, N.S.H.N.; Ramasamy, S.; Vanam, U.; Manivannan, E.; Karunagaran, D.; Trivedi P. Advances in Chalcones with Anticancer Activities. Rect Pat. Anti-Cancer Drug Discov., 2015, 10, 97-115.
48. Matos, M.J.; Vazquez-Rodriguez, S.; Uriarte, E.; Santana, L. Potential pharmacological uses of chalcones: a patent review. Expert Opin. Ther. Pat., 2015, 25(3) 351-66.
49. Mahapatra, D.K.; Asati, V.; Bharti, S.K. Chalcones and their therapeutic targets for the management of diabetes: Structural and pharmacological perspectives. Eur. J. Med. Chem., 2015, 92, 839-865.
50. Sahu, N.K.; Balbhadra, S.S.; Choudhary, J.; Kohli, D.V. Exploring pharmacological significance of chalcone scaffold: A review. Curr. Med. Chem., 2012, 19, 209-225.
51. Jandial, D.D.; Blair, C.A.; Zhang, S.; Krill, L.S.; Zhang, Y.B.; Zi X. Molecular targeted approaches to cancer therapy and prevention using chalcones. Curr. Cancer Drug Tar., 2014, 14, 181-200.
52. Batovska, D.L.; Todorova, I.T. Trends in utilization of the pharmacological potential of chalcones. Curr. Clin. Pharmacol., 2010, 5, 1-29.
53. Zhao L.M.; Jin, H.S.; Sun, L.P.; Piao, H.R.; Quan, Z.S. Synthesis and evaluation of antiplatelet activity of trihydroxychalcone derivatives. Bioorg. Med. Chem. Lett., 2005, 15, 5027-5029.
54. Sui, X.; Quan, Y.C.; Chang, Y.; Zhang, R.P.; Xu, Y.F.; Guan, L.P. Synthesis and studies on antidepressant activity of 2ʹ, 4ʹ, 6ʹ- trihydroxychalcone derivatives. Med. Chem. Res., 2012, 21, 1290-1296.
55. Afzal, O.; Bawa, S.; Kumar, S.; Kumar, R.; Hassan Md. Q. Design, synthesis and evaluation of novel 2-piperidinyl quinoline chalcones/ amines as potential antidepressant agents. Lett. Drug Des. Discov., 2013, 10, 75-85.
56. Hasan, A.; Khan, K.M.; Sher, M.; Maharvi, G.M.; Nawaz, S.A.; Choudhary, M.I.; Rahman A.U.; Supuran, C.T. Synthesis and inhibitory potential towards acetylcholinesterase, butyrylcholinesterase and lipoxygenase of some variably substituted chalcones. J. Enzyme Inhib. Med. Chem. 2005, 20, 41-47.
57. Liu, H.R.; Liu, X.J.; Fan, H.Q.; Tang, J.J.; Gao, X.H.; Liu, W.K. Design, synthesis and pharmacological evaluation of chalcone derivatives as acetylcholinesterase inhibitors. Bioorg. Med. Chem. 2014, 22, 6124-6133.
58. Liu, H.R.; Zhou, C.; Fan, H.Q.; Tang, J.J.; Liu, L.B.; Gao, X.H.; Wang, Q.A.; Liu, W.K. Novel potent and selective acetylcholinesterase inhibitors as potential drugs for the treatment of Alzheimer's disease: Synthesis, pharmacological evaluation, and molecular modeling of amino-alkyl-substituted fluoro-chalcones derivatives. Chem. Biol. Drug Des., 2015. doi: 10.1111/cbdd.12514.
59. Mathew, B.; Suresh, J.; Mathew, G.E.; Parasuraman R.; Abdulla, N. Plant secondary metabolites- Potent inhibitors of monoamine oxidase isoforms. Cent. Nerv. Syst. Agents Med. Chem. 2014, 14, 28-33.
60. Tanaka, S.; Kuwai, Y.; Tabata M. Isolation of Monoamine oxidase from Glycyrrhiza uralensis roots and the structure activity relationship. Planta Med., 1987, 53, 5-8.
61. Hatano, T.; Fukuda, T.; Miyase, T.; Noro, T.; Okuda, T. Phenolic constituents licorice III. Structures of Glicoricone and Licofuranone and inhibitory effects of licorice constituents on monoamine oxidase enzyme. Chem. Pharm. Bull., 1991, 39, 1238-1243.
62. Pan, X.; Kong, L. D.; Zhang, Y.; Cheng, C. H.; Tan, R. X In vitro inhibition of rat monoamine oxidase by liquiritigenin and isoliquiritigenin isolated from Sinofranchetia chinensis. Acta Pharmacol. Sinica 2000, 21, 949-953.
63. Haraguchi, H.; Tanaka, Y.; Kabbash, A.; Fujioka, T.; Ishizu, T.; Yagi, A. Monoamine oxidase inhibitors from Gentiana lutea. Phytochemistry 2004, 65, 2255-2260.
64. Kim, J.H.; Son, Y.K.; Kim, G.H, Hwang, K.H. Xanthoangelol and 4-Hydroxyderricin are the major active principles of the inhibitory activities against monoamine oxidases on Angelica keiskei k. Biomol. Ther., 2003, 21, 234-240.
65. Chimenti, F.; Fioravanti, R.; Bolasco, A.; Chimenti, P.; Secci, D.; Rossi, F.; Yanez, M.; Orallo, F.; Ortuso, F.; Alcaro, S. Chalcones: A valid scaffold for monoamine oxidases inhibitors. J. Med. Chem., 2009, 52, 2818-2824.
66. Helguera A.M.; Pérez-Machado G, Cordeiro, M.N.D.S.; Borges, F. Discovery of MAO-B Inhibitors - Present status and future directions. part I: Oxygen heterocycles and analogs. Mini Rev. Med. Chem., 2012, 12.
67. Robinson, S J, Petzer, J. P, Petzer, A.; Bergh J J, Lourens, A.C.U. Selected furanochalcone as inhibitors of monoamine oxidase. Bioorg. Med. Chem. Lett., 2013, 23, 4985-4989.
68. Jo, G.; Ahn S.; Kim, B.G.; Park, H.R.; Kim, Y.H.; Cho, A.H.; Koh, D.; Chong, Y.; Ahn, J.H.; Lim, Y. Chromenyl chalcones with inhibitory effects on monoamine oxidase B. Bioorg. Med. Chem., 2013, 21, 7890-7897.
69. Evranos-Aksöz, B.; Yabanoğlu-Çiftçi, S.; Uçar, G.; Yelekçi, K.; Ertan, R. Synthesis of some novel hydrazone and 2-pyrazoline derivatives: Monoamine oxidase inhibitory activities and docking studies. Bioorg. Med. Chem. Lett., 2014, 24, 3278-3284.
70. Morales-Camilo, N.; Salas, C.O.; Sanhueza, C.; Espinosa-Bustos, C.; Sepúlveda-Boza, S.; Reyes-Parada, M.; Gonzalez-Nilo, F.; Caroli-Rezende, M.; Fierro, A. Synthesis, biological evaluation, and molecular simulation of chalcones and aurones as selective MAO-B inhibitors. Chem. Biol. Drug Des., 2015, 85, 685-695.
71. Mathew, B.; Mathew, G.E.; Uçar, G.; Baysal, I.; Suresh, J.; Vilapurathu, J.K.; Prakasan, A.; Suresh, J.K.; Thomas, A. Development of fluorinated methoxylated chalcones as selective monoamine oxidase- B inhibitors: Synthesis, biochemistry and molecular docking studies. Bioorg. Chem., 2015, 62, 22-29.
72. Zaib, S.; Rizvi S.U.F.; Aslam, S.; Ahmad, M.; Abid, S.M.A.; al-Rashida, M.; Iqbal, J. Quinolinyl-Thienyl chalcones as monoamine oxidase inhibitors and their in silico modeling studies. Med. Chem., 2015, 11, 580-589.
73. Zaib, S.; Rizvi S.U.F.; Aslam, S.; Ahmad, M.; al-Rashida, M.; Iqbal, J. Monoamine oxidase inhibition and molecular modeling studies of piperidyl-thienyl and 2-pyrazoline derivatives of chalcones. Med. Chem., 2015, 11, 497-505.
74. Evranos-Aksöz, B.; Yabanoğlu-Çiftçi, S.; Dijikic, T.; Yelekçi, K.; Uçar, G.; Ertan, R. Synthesis and screening of human Monoamine oxidase-A inhibitor effect of new 2-pyrazoline and hydrazone derivatives. Arch. Pharm. Chem. Life, 2015, 348, 743-756.
75. Choi, J.W.; Jang B.K.; Cho, N.; Park, J.H.; Yeon, S.K.; Ju, E.J.; Lee, Y.S.; Han, G.; Pae, A.M.; Kim, D.J.; Park. K.D. Synthesis of a series of unsaturated ketone derivatives as selective and reversible monoamine oxidase inhibitors. Bioorg. Med. Chem., 2015, 23, 6486-6496.
76. Mathew, B.; Uçar, G.; Yabanoğlu-Çiftçi, S.; Baysal, I.; Suresh, J.; Mathew, G.E.; Vilapurathu, J.K.; Nadeena A.M.; Nabeela, P.; Lakshmi, V.; Haridas, A.; Fathima, F. Development of fluorinated thienylchalcones as monoamine oxidase-b inhibitors: Design, synthesis, biological evaluation and molecular docking studies. Lett. Org. Chem., 2015, 12, 605-613.
77. Minders, C.; Petzer, J. P.; Petzer, A.; Lourens, A.C.U. Monoamine oxidase inhibitory activities of heterocyclic chalcones. Bioorg. Med. Chem. Lett., 2015, 25(22), 5270-76.
78. Binda, C.; Newton-Vinson, P.; Hubálek, F.; Edmondson, D.E.; Mattevi, A. Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders. Nat. Struct. Biol., 2002, 9, 22-26.
79. Ruan, B.F.; Cheng, H.J.; Ren, J.; Li, H.L.; Guo, L.L.; Zhang, X.X.; Liao C. Novel 2H-chromen-2-one derivatives of resveratrol: Design, synthesis, modeling and use as human monoamine oxidase inhibitors. Eur. J. Med. Chem. doi: 10.1016/j.ejmech.2015.08.055.
80. Novaroli, L.; Daina, A.; Favre, E.; Bravo, J.; Carotti, A.; Leonetti, F.; Catto, M.; Carrupt, P.A.; Reist, M. Impact of species-dependent differences on screening, design, and development of MAO B inhibitors. J. Med. Chem., 2006, 49, 6264-6272.
81. Legoabe, L.; Kruger, J.; Petzer, A.; Bergh, J.J.; Petzer. J.P. Monoamine oxidase inhibition by selected anilide derivatives. Eur. J. Med. Chem., 2011, 46, 5162-5174.
82. Binda, C.; Li, M.; Hubálek, F.; Restelli, N.; Edmondson, D.E.; Mattevi, A. Insights into the mode of inhibition of human mitochondrial monoamine oxidase B from high-resolution crystal structures. Proc. Natl. Acad. Sci. U.S.A., 2003, 100, 9750-9755.
83. Bender, A.; Glen, R.C. Molecular similarity: A key technique in molecular informatics. Org. Biomol. Chem., 2004, 2, 3204-3218.
84. Vaz de Lima, L.A.; Nascimento, A.S. MolShaCS: A free and open source tool for ligand similarity identification based on Gaussian descriptors. Eur. J. Med. Chem., 2013, 59, 296-303.
85. Damier, P.; Kastner, A.; Agid, Y.; Hirsch, E.C. Does monoamine oxidase B play a role in dopaminergic nerve cell death in Parkinson’s disease? Neurology, 1996, 46, 1262-1269.
86. Carreiras, M.C.; Marco, J.L. Recent approaches to novel anti- Alzheimer’s therapy. Curr. Pharm. Des., 2004, 10, 3167-3175.
87. Youdim, M.B.H.; Gross, A.; M Finberg, J.P.M. Rasagiline [Npropargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br. J. Pharmacol., 2001, 132, 500-506.
88. Hoy, S M.; Keating, G.M. Rasagiline: A review of its use in the treatment of idiopathic Parkinson's disease. Drugs, 2012, 72, 643-669.
89. Müller, T.; Hoffmann, J.A.; Dimpfel, W.; Oehlwein, C. Switch from selegiline to rasagiline is beneficial in patients with Parkinson's disease. J. Neuro. Transm., 2013, 120, 761-765.
90. Carradori, S.; Silvestri, R. New Frontiers in Selective Human MAO.B Inhibitors. J. Med. Chem., 2015, 58, 6717-6732.
91. Legoabe, L.J.; Petzer, A.; Petzer, J.P. The Synthesis and evaluation of C7-Substituted α-Tetralone derivatives as inhibitors of Monoamine oxidase. Chem. Biol. Drug Des., 2015, 86, 895-904.
92. Secci, D.; Carradori, S.; Bolascoa, A.; Bizzarria, B.; D’Ascenzioa, M.; Maccioni, E. Discovery and optimization of pyrazoline derivatives as promising Monoamine oxidase inhibitors. Curr. Top. Med. Chem., 2012, 12, 2240-2257.
93. Mathew, B.; Suresh, J.; Anbazhagan, S.; Mathew, G.E. Pyrazoline: A promising scaffold for the inhibition of Monoamine oxidase. Cent. Nerv. Syst. Agents Med. Chem., 2013, 13, 195-206